Table 1.
First author | Country | Viral Etiology | Patients | CP dose | Outcome endpoint | Clinical improvement | Death | Viral therapy | Adverse event | Weaned ventilation | Discharge | Drugs | Ref |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Li | China | SARS-CoV-2 | 52 case 51 control |
S-RBD–IgG 1:640 200 ml |
28 days | 27/52 22/51 |
15.7% 24% |
87.2% 37.5% |
2/0 | NA | 51% 36% |
Antiviral, antibacterial, antifungal, interferon, steroids | [25] |
Shen | China | SARS-CoV-2 | 5 | IgG (1:1000) 200-250 ml |
12 days | 3 | 0 | 5 | NA | 3 | 3 | Lopinavir/ritonavir, favipiravir, interferon alfa-1b, arbidol, darunavir | [26] |
Joyner | USA | SARS-CoV-2 | 5000 | IgG 500 ml |
7 days | NA | 602 | NA | 36 | NA | NA | NA | [27] |
Zeng | China | SARS-CoV-2 | 6/15 | IgG 300 ml |
22 days | 6 | 5/6 14/15 |
6/3 | 0 | NA | 1/1 | NA | [28] |
Ahn | Korea | SARS-CoV-2 | 2 | IgG 500 ml |
26 days | 2 | 0 | 2 | 0 | 2 | 2 | Lopinavir/ritonavir, hydroxychloroquine, methylprednisolone, antibiotics | [29] |
Ye | China | SARS-CoV-2 | 6 | IgG 400-600 ml |
33 days | 5 | 0 | 2 | 0 | NA | 3 | Arbidol, levofloxacin | [30] |
Zhang | China | SARS-CoV-2 | 4 | IgG 200-400 ml |
NA | 4 | 0 | 4 | 0 | 2 | 4 | Arbidol, lopinavir-ritonavir, interferon alpha | [31] |
Duan | China | SARS-CoV-2 | 10 | IgG 1:640 200 ml |
20 days | 10 | 0 | 7 | 0 | 3 | 10 | Arbidol, remdesivir, ribavirin, peramivir, antibacterial | [32] |
Ko | Korea | MERS-CoV | 3 | IgG 1:80 |
3 days | 3 | 0 | 2 | NA | 3 | 3 | NA | [33] |
Chun | Korea | MERS-CoV | 1 | IgG 500 ml |
NA | 1 | 0 | NA | 1 | NA | 1 | Ribavirin, lopinavir/ritonavir, interferon alpha | [34] |
Wong | China | SARS-CoV-1 | 1 | IgG 200 ml |
NA | 1 | 0 | NA | 0 | NA | 0 | Cefotaxime, levofloxacin, oseltamivir, ribavirin | [35] |
Yeh | Taiwan | SARS-CoV-1 | 3 | IgG 1:640 500 ml |
NA | 3 | 0 | 2 | NA | 1 | 3 | Lopinavir, ritonavir, methylprednisolone | [36] |
Soo | China | SARS-CoV-1 | 19/21 | IgG 600-900 ml |
22 days | 14/4 | 0/5 | NA | 0 | NA | 74% 19% |
Ribavirin, methylprednisolone |
[37] |
Kong | China | SARS-CoV-1 | 1 | IgG 500 ml |
7 days | 1 | 0 | NA | NA | 1 | 1 | Steroids, antiviral | [38] |
Cheng | China | SARS-CoV-1 | 40 | IgG 600-900 ml |
22 days | 40 | 13 | NA | 0 | NA | 26 | Cefotaxime, levofloxacin, ribavirin, prednisolone, methylprednisolone | [39] |